Phase 3 Clinical Trials With Primary Completion Dates in September 2022
This is a list of Phase 3 trials with primary completion dates in September 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc. | 2022-09-01 | Phase 3 | NCT04227106 | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
| ATHA | Athira Pharma, Inc. | 2022-09-01 | Phase 3 | NCT04488419 | ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease |
| ATHX | Athersys, Inc. | 2022-09-01 | Phase 3 | NCT03545607 | MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study |
| CNTA | Centessa Pharmaceuticals plc | 2022-09-01 | Phase 3 | NCT04152837 | Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease |
| HLBBF | H. Lundbeck A/S | 2022-09-01 | Phase 3 | NCT03594123 | A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type |
| MEDP | Medpace Holdings, Inc. | 2022-09-01 | Phase 3 | NCT03545607 | MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study |
| MIRM | Mirum Pharmaceuticals, Inc. | 2022-09-01 | Phase 3 | NCT03905330 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) |
| MRTX | Mirati Therapeutics, Inc. | 2022-09-01 | Phase 3 | NCT03906071 | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer |
| NEPH | Nephros, Inc. | 2022-09-01 | Phase 3 | NCT04459338 | A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion |
| NEPH | Nephros, Inc. | 2022-09-01 | Phase 3 | NCT04591015 | Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19 |
| NVCR | NovoCure Limited | 2022-09-01 | Phase 3 | NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). |
| ONPH | Oncology Pharma Inc. | 2022-09-01 | Phase 3 | NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy |
| PHAT | Phathom Pharmaceuticals, Inc. | 2022-09-01 | Phase 3 | NCT05195528 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) |
| PYPD | PolyPid Ltd. | 2022-09-01 | Phase 3 | NCT03558984 | D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery |
| RIGL | Rigel Pharmaceuticals, Inc. | 2022-09-01 | Phase 3 | NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects |
| RLMD | Relmada Therapeutics, Inc. | 2022-09-01 | Phase 3 | NCT04688164 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| RNXT | RenovoRx, Inc. | 2022-09-01 | Phase 3 | NCT03257033 | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
| SCYX | SCYNEXIS, Inc. | 2022-09-01 | Phase 3 | NCT03059992 | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment |
| SELB | Selecta Biosciences, Inc. | 2022-09-01 | Phase 3 | NCT04596540 | A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II |
| STSA | Satsuma Pharmaceuticals, Inc. | 2022-09-01 | Phase 3 | NCT04940390 | A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine |
| SYNH | Syneos Health, Inc. | 2022-09-01 | Phase 3 | NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| TNDM | Tandem Diabetes Care, Inc. | 2022-09-01 | Phase 3 | NCT04233034 | Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes |
| VAXX | Vaxxinity, Inc. | 2022-09-01 | Phase 3 | NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| XFOR | X4 Pharmaceuticals, Inc. | 2022-09-01 | Phase 3 | NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome |